A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 6, 2017

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Arthritis, Psoriatic
Trial Locations (21)

8233GT / 8303 BX

Reumazorg ZWN, Lelystad/Emmeloord

3844DG

St. Jansdal, Harderwijk

5912 BL

Viecuri Medisch Centrum, Venlo

Research Site, Venlo

4819 EV

Amphia, Breda

5707 HA

Elkerliek ziekenhuis, Helmond

4707 CH

Reumazorg ZWN, Roosendaal

Research Site, Roosendaal

8934 AD

MC Leeuwarden, Leeuwarden

Research Site, Leeuwarden

4204 AA

Beatrix Ziekenhuis, Gorinchem

Research Site, Gorinchem

2803 HH

Groene Hart Ziekenhuis, Gouda

Research Site, Gouda

3015 CE

Erasmus MC, Rotterdam

Research Site, Rotterdam

3079 DZ

Maasstad Ziekenhuis, Rotterdam

Research Site, Rotterdam

4462 EV

Reumazorg ZWN, Goes

4818 CK

Research Site, Breda

3844 DG

Research Site, Harderwijk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02875184 - A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands | Biotech Hunter | Biotech Hunter